We would love to hear your thoughts about our site and services, please take our survey here.
Any early signs of efficacy in the data will have a positive effect on the ph1b trial design as they could effectively create a ph1b which behaves like a ph2 esp. if the safety is significantly superior to the normal allosteric Tyk2 approach.
Haha funny- yes we've all contributed to this for s.its and giggles oh and there's a 20p death cross death spiral placing coming. So 80p is masssively overvalued come back next year and we'll let you know when to invest.
Toodle pip now byeee
"During second quarter earnings calls, many heavy-hitters—including Johnson & Johnson, Bristol Myers Squibb and Merck—expressed urgency in their quest for deals. With so many buyers in competition, sellers are finding offers that are more attractive".
Hoping this is the reason for the delay in Chk1 news.
Good to know then that we have had 2 new patents this year- a Chinese specific for 1801 and a US auto-immune for 1802.
https://www.fiercepharma.com/pharma/patient-cliffs-divestitures-and-biotechs-maturing-its-prime-time-ma-analysts
Many happy returns chaps- IP is the buzz word it seems as Thoth always mentioned.
Also mention this regwrds to 1801-
11.18- Dr Reader advising Australia has a streamline and efficient approval process and good access to Psoriasis patients.
18.10- Dr Reader advising human data generated in Australia is accepted by FDA, EMA, MHRA and Japanese authority. Data is perfectly acceptable to authorities around the globe.
23.43- Will be working with dermatology clinics who will be referring patients suitable for the trial, which was on of the attractions on taking trials to Australia and availability of Psoriasis patients.
25.00- Ph1b could be bought back to UK or Europe for other disease areas also but not the plan but don't want to close any doors.
1802-
https://m.youtube.com/watch?v=KJFhOEmaPFw
12.10- Dr Reader on 1802, it has shown good efficacy in pre-clinical cancer and just need to complete translational studies to define optimal cancer application and then select cancer population and begin ph1 trials.
12.40- 1801 and 1802 derived from same chemical class, so can push forward with 1802 learning from 1801 experience.
26.15- 1802 translation studies are in progress and done some short term acute tox studies already all of which were fine. Manufacture will be in line with 1801 process so no hanging about when they are ready.
27.20- 1802 will begin clinical trials in patients not healthy subjects.
Australia is built on first-in-human on healthy subjects so may not be in Australia.
And will be quiete a different ph1 clinical trial than that envisaged for 1801.
That was from the half-yearly so would be interested to know how it has progressed.
Gunner, I think the focus is squarely on 1801 everything else should be seen as a bonus.
For me the most promising thing insofar is moving to part 2 of the ph1a trial after just 3 out of 6 recommended cohorts by the safety committee and then furthermore going on a dual trial with a muslti-ascending dose study.
In regards to price movement, I don't think we will move significantly until ph1a pk data is published and we have clear sight of what dose and tox tolerance etc will be used for the ph1b efficacy trial.
It's coming don't worry chaps- just need to observe some patience and we're accustomed to that anyway.
We have the final results soon and in regards to part 3 of 1801 trial the website said this so mid to late Nov could also get some news-
Each participant will be in the study for approximately 9 weeks (Screening Visit to Follow-up Visit) and will receive 2 doses of SDC-1801.
There we go again- no adverse effects. Who was that fella who tried to FUD that adverse effects issue?
Anyhoo, as we go marching on we get ever closer to safety being nailed on and gangbustering to ph1b Dr Readers gamechanging phase.
Many happy returns chaps- where have all the t... gone 😉
I don't know the first thing about charts- but if it goes lower the better for me as it looks like I am going to have that 8k earlier than expected to invest here.
In regards to chk1 out of our hands but in the hands of Cancer Research so no better hands to be honest. And Gunner getting to clinic with a 100% owned compound is everything we need to shout about but also chk1 getting to ph2/3 ready and showing 80% tumour reduction in combo therapy is another thing to shout about.
We may lambast Sierra for prioritising momo and semi-backbenching Chk1 but not many majors would have gone gangbusters as they did in progressing Chk1 and getting patents to where we are now- ph2/3 ready compounds are worth in excess of 500m standalone but as we have shown efficacy in combo therapy with already FDA approved drugs Chk1 id worth over 1.5bn in my opinion unless anyone can suggest differently with some research and evidence.
That'll be Christies in Manchester among others as per this article-
https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://christie.openrepository.com/bitstream/handle/10541/625774/36378548.pdf%3Fsequence%3D1&ved=2ahUKEwjE3u7gz7SBAxWJW0EAHY6HB88QFnoECBEQAQ&usg=AOvVaw2-CN-0SgFCSu4b6a7vzhk2